Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;38(2):379-396.
doi: 10.1016/j.ncl.2020.01.004. Epub 2020 Feb 28.

Treatment of Tardive Dyskinesia

Hassaan H Bashir  1 , Joseph Jankovic  2
Affiliations
Review

Treatment of Tardive Dyskinesia

Hassaan H Bashir et al. Neurol Clin. 2020 May.

Abstract

Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality of life. Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high. The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission. Dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered the treatment of choice of TD.

Keywords: Deutetrabenazine; Tardive dyskinesia; Tardive syndrome; VMAT2 inhibitors; Valbenazine.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr H.H. Bashir has nothing to disclose. Dr J. Jankovic has received research/training funding from Allergan; CHDI Foundation; Dystonia Coalition; F. Hoffmann-La Roche Ltd; Huntington Study Group; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neurocrine Biosciences; Parkinson's Foundation; Parkinson Study Group; Revance Therapeutics, Inc; and Teva Pharmaceutical Industries. He has served as a consultant/advisory board member for Abide; Aeon BioPharma; Nuvelution; Retrophin; and Teva Pharmaceutical Industries Ltd. He has served on editorial boards of Expert Review of Neurotherapeutics; Journal of Parkinson’s Disease; Medlink; Neurology in Clinical Practice; The Botulinum Journal; PeerJ; Therapeutic Advances in Neurologic Disorders; Neurotherapeutics; Tremor and Other Hyperkinetic Movements; Toxins; and UpToDate. He has received royalties from Cambridge; Elsevier; Future Science Group; Hodder Arnold; Medlink: Neurology; Lippincott Williams and Wilkins; and Wiley-Blackwell.

MeSH terms

LinkOut - more resources